Home Cart Sign in  
Chemical Structure| 4136-37-2 Chemical Structure| 4136-37-2

Structure of Stachydrine HCl
CAS No.: 4136-37-2

Chemical Structure| 4136-37-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Stachydrine HCl is a naturally occuring anti-metastatic agent in vitro which is isolated from seed husk and the pulp of the fruit of C. Leonurus.

Synonyms: Stachydrine hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Stachydrine HCl

CAS No. :4136-37-2
Formula : C7H14ClNO2
M.W : 179.64
SMILES Code : C[N+]1(C)[C@H](C(O)=O)CCC1.[Cl-]
Synonyms :
Stachydrine hydrochloride
MDL No. :MFCD21609192
InChI Key :DUNMULOWUUIQIL-RGMNGODLSA-N
Pubchem ID :44150282

Safety of Stachydrine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Stachydrine HCl

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Adult mouse cardiac myocytes (AMCMs) 10 µM 1 hour STA decreased Ca2+ content, enhanced contractility, inhibited Ca2+ overload, and strengthened sarcomere contractility in cardiomyocytes under oxidative stress. Int J Mol Sci. 2023 Sep 21;24(18):14369
Bovine aorta endothelial cells (BAECs) 10 µM 12 hours To evaluate the effect of STA on Hcy-induced reduction in NO production, results showed that STA pretreatment effectively attenuated the detrimental effect of Hcy on NO production. Mol Med. 2018 Mar 19;24(1):10
Bovine aorta endothelial cells (BAECs) 0-10 µM 24 hours To evaluate the effect of STA on cell viability, results showed that STA had no significant effect on BAECs viability at concentrations of 0-20μM. Mol Med. 2018 Mar 19;24(1):10
HUVEC cells 10 µM 24 hours To evaluate the inhibitory effect of Stachydrine on M2-TAMs-induced migration, invasion, and tube formation of HUVEC cells. Results showed that Stachydrine significantly inhibited M2-TAMs-induced migration, invasion, and tube formation of HUVEC cells. Front Pharmacol. 2025 Feb 5;16:1514158
THP-1 cells 10 µM 24 hours To evaluate the inhibitory effect of Stachydrine on M2-TAMs-induced migration and invasion of CRC cells. Results showed that Stachydrine significantly inhibited M2-TAMs-induced migration and invasion of CRC cells. Front Pharmacol. 2025 Feb 5;16:1514158
Rat H9c2 cardiomyocytes 10 µM 24 hours STA decreased the expression of phosphorylated CaMKII (T286), oxidized CaMKII, and phosphorylated RyR2 (S2814) proteins. Int J Mol Sci. 2023 Sep 21;24(18):14369
HK-2 cells 20 or 40 µM 36 hours To evaluate the effects of stachydrine on HK-2 cell viability and oxidative stress. Results showed that stachydrine significantly reduced ROS levels and enhanced the expression of antioxidant enzymes. Foods. 2025 May 12;14(10):1718
Neonatal rat cardiomyocytes (NRCMs) 10 µM 48 hours STA reduced ROS production, downregulated NOX2 protein expression, and regulated the translocation of its regulatory subunits in hypertrophic cardiomyocytes. Int J Mol Sci. 2023 Sep 21;24(18):14369
Bone marrow-derived macrophages (BMMs) 0, 12.5, 25, 50, 100, 200 µM 5 days STA inhibited RANKL-induced osteoclast formation in a dose-dependent manner J Cell Mol Med. 2019 Oct;23(10):6730-6743
PC12 cells 10 mM 6 hours To investigate the protective effect of stachydrine on oxygen-glucose deprivation (OGD)-induced injury in PC12 cells, results showed that stachydrine improved the survival rate of PC12 cells and reduced the release of inflammatory factors Front Pharmacol. 2020 Feb 18;11:64
Cardiac fibroblasts 1-100 µM 96 hours Sta significantly inhibited AngII-induced proliferation and trans-differentiation of cardiac fibroblasts into myofibroblasts, and down-regulated the ACE/AngII/AT1R-TGFβ1 fibrogenic axis Front Pharmacol. 2019 May 22;10:538
Bone marrow-derived macrophages (BMMs) 100 µM Early stage (days 1-3) STA significantly inhibited osteoclast formation in the early stage J Cell Mol Med. 2019 Oct;23(10):6730-6743

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LPS-induced inflammatory bone loss model Intragastric administration 10 mg/kg Once daily for 7 days STA alleviated LPS-induced bone loss and reduced osteoclast number J Cell Mol Med. 2019 Oct;23(10):6730-6743
Sprague-Dawley rats Hyperhomocysteinemia-induced endothelial dysfunction model Ex vivo organ culture 10 μM 12 hours To evaluate the protective effect of STA on Hcy-induced endothelial dysfunction, results showed that STA effectively restored Hcy-impaired vascular relaxation. Mol Med. 2018 Mar 19;24(1):10
C57BL/6 mice Pressure overload-induced cardiac fibrosis model Oral gavage 12 mg/kg Once daily for 4 weeks Sta significantly attenuated pressure overload-induced cardiac fibrosis, improved cardiac function and morphological remodeling, and down-regulated the ACE/AngII/AT1R-TGFβ1 fibrogenic axis Front Pharmacol. 2019 May 22;10:538
C57BL/6J mice Colorectal cancer liver metastasis model Oral 15 mg/kg/d, 30 mg/kg/d, 60 mg/kg/d Every other day for 3 weeks To evaluate the inhibitory effect of Stachydrine on colorectal cancer liver metastasis. Results showed that Stachydrine significantly reduced the number and size of liver metastases and prolonged the survival of mice. Front Pharmacol. 2025 Feb 5;16:1514158
Sprague-Dawley rats Middle Cerebral Artery Occlusion (MCAO) model Caudal vein injection 167.60 mM Once daily for 24, 48, or 72 hours To investigate the protective effect of stachydrine on cerebral ischemia-reperfusion injury, results showed that stachydrine significantly reduced the infarct volume, improved neurological deficit scores, and decreased the levels of inflammatory factors IL-1β and TNF-α Front Pharmacol. 2020 Feb 18;11:64
ICR mice Hyperuricemia model induced by high-nucleoside diet Intragastric administration 20 or 40 mg/kg Once daily for 4 weeks To evaluate the effects of stachydrine on uric acid levels and renal injury in hyperuricemic mice. Results showed that stachydrine significantly reduced serum uric acid levels and alleviated renal inflammation and oxidative stress. Foods. 2025 May 12;14(10):1718
C57BL/6J mice Transverse aortic constriction (TAC)-induced heart failure model Gavage 6 mg/kg/d or 12 mg/kg/d Once daily for 6 weeks STA improved cardiac function and morphology, reduced ROS production and NOX2 protein expression, inhibited NOX2-related calcium overload, and enhanced sarcomere contractility. Int J Mol Sci. 2023 Sep 21;24(18):14369

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.57mL

1.11mL

0.56mL

27.83mL

5.57mL

2.78mL

55.67mL

11.13mL

5.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories